来凯医药-b(02105)涨超9%,截至发稿,涨9.1%,报19.66港元,成交额6468.18万港元。消息面上,来凯医药近日宣布,其自主研发针对ActRIIA的单克隆抗体LAE102,在美国针对肥胖症治疗的一项I期临床试验已完成首位受试者给药。该试验计划于2025年9月完成主要研究阶段。同时,LAE102在中国的I期多剂量递增(MAD)研究,来凯医药将按计划在2025年9月底前完成初步数据。此外...
Source Link来凯医药-b(02105)涨超9%,截至发稿,涨9.1%,报19.66港元,成交额6468.18万港元。消息面上,来凯医药近日宣布,其自主研发针对ActRIIA的单克隆抗体LAE102,在美国针对肥胖症治疗的一项I期临床试验已完成首位受试者给药。该试验计划于2025年9月完成主要研究阶段。同时,LAE102在中国的I期多剂量递增(MAD)研究,来凯医药将按计划在2025年9月底前完成初步数据。此外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.